Buy Atenolol-Teva tablets 50 mg No. 30 in pharmacies
Atenolol Buy Atenolol in pharmacies
DOSAGE FORMS tablets 50mg film-coated tablets 50g film-coated tablets 50mg
GROUP Beta1-blockers (cardioselective)
COMPOSITION Active substance - Atenolol.
INTERNATIONAL NON-PROPENTED NAME Atenolol
SYNONYMS Atenobene, Atenova, Atenol, Atenolol Belupo, Atenolol Nycomed, Atenolol FPO, Atenolol-Agio, Atenolol-AKOS, Atenolol-Acri, Atenolol-Teva, Atenolol-UBF, Atenosan, Atcardil, Betacard, Betacard-100, Betacard-50, Vascoten, Prinorm, Tenolol, Tenormin, Hypoten
PHARMACOLOGICAL ACTION Hypotensive, antianginal, antiarrhythmic. Reduces heart rate (HR) both at rest and during physical activity. The negative chronotropic effect appears after 1 hour, reaches a maximum after 2-4 hours and continues for up to 24 hours. Reduces cardiac output, systolic blood pressure and diastolic blood pressure, reduces orthostatic tachycardia. The antihypertensive effect lasts 24 hours. Reduces myocardial oxygen demand. Increases survival of patients who have had myocardial infarction (reduces the frequency of ventricular arrhythmias and angina attacks). Slightly reduces the vital function of the lungs, practically does not weaken the bronchodilatory effect of isoproterenol. It penetrates poorly through the blood-brain barrier, passes through the placental barrier and into breast milk. It is practically not metabolized in the liver and is excreted by the kidneys through glomerular filtration.
INDICATIONS FOR USE Arterial hypertension, angina pectoris, acute myocardial infarction (with stable hemodynamic parameters), tachycardia: sinus, atrial, ventricular, paroxysmal, etc., extrasystole, atrial flutter and fibrillation, hyperkinetic cardiac syndrome, mitral valve prolapse, neurocirculatory dystonia due to hypertensive type; complex therapy of hypertrophic cardiomyopathy, pheochromocytoma, thyrotoxicosis, essential tremor; migraine (prevention).
CONTRAINDICATIONS Hypersensitivity, sinus bradycardia (heart rate less than 50 beats/min), sinoatrial block, sick sinus syndrome, AV block II-III degree, arterial hypotension (systolic blood pressure less than 90 mm Hg), acute or chronic cardiac failure in the stage of decompensation, cardiogenic shock, peripheral circulatory disorders, breastfeeding.
SIDE EFFECTS From the nervous system and sensory organs: increased fatigue, weakness, dizziness, headache, drowsiness or insomnia, nightmares, depression, anxiety, confusion or short-term memory loss, hallucinations, decreased reactivity, paresthesia, convulsions; blurred vision, decreased secretion of saliva and tear fluid, conjunctivitis. From the cardiovascular system and blood (hematopoiesis, hemostasis): bradycardia, palpitations, myocardial conduction disturbances, AV block, arrhythmias, weakened myocardial contractility, heart failure, hypotension, syncope, Raynaud's phenomenon, vasculitis, chest pain, thrombocytopenia, agranulocytosis . From the gastrointestinal tract: dry mouth, nausea, vomiting, abdominal pain, diarrhea, constipation, liver dysfunction. From the respiratory system: shortness of breath, laryngo- and bronchospasm. Allergic reactions: itching, rash, erythema, urticaria, psoriasis-like and dystrophic skin changes. Other: reversible alopecia, hyperhidrosis, cold extremities, myasthenia gravis, decreased libido, impotence, Peyronie's disease, changes in enzyme activity, bilirubin levels, withdrawal syndrome, hypothyroid state, hypoglycemia.
INTERACTION Antiarrhythmic and anesthetic drugs enhance the cardiodepressive effect (increases the risk of developing bradycardia, arrhythmia, hypotension, heart failure). Reserpine, alpha-methyldopa, clonidine, guanfacine, cardiac glycosides potentiate the negative chrono-, dromo- and bathmotropic effect, insulin and other antidiabetic drugs - hypoglycemia. NSAIDs, estrogens, sympathomimetics, xanthines weaken the hypotensive effect, absorption, increase - sympatholytics, nitroglycerin, apressin and other antihypertensive drugs, antacids - slow down absorption. Cimetidine inhibits metabolism. Prolongs the effect of antidepolarizing muscle relaxants, the anticoagulant effect of coumarins. Tri/tetracyclic antidepressants, antipsychotics, sedatives, hypnotics and alcohol potentiate CNS depression. Incompatible with MAO inhibitors.
METHOD OF APPLICATION AND DOSAGE Orally, before meals, without chewing and with a small amount of liquid. The dosage regimen is set individually. For arterial hypertension - 25-50 mg once, if necessary, 100-200 mg 1-2 times a day. For coronary heart disease, tachysystolic heart rhythm disturbances - 50 mg 1 time per day; if necessary and well tolerated, the dose can be increased within a week to 100-200 mg/day. In case of acute myocardial infarction with stable hemodynamic parameters - after 12 hours - again 50 mg; then - 50 mg 2 times a day for 6-9 days (under the control of blood pressure, ECG, glucose levels). For functional disorders of the cardiovascular system - 25 mg 1 time per day. In case of impaired renal function, depending on creatinine clearance: with a clearance of 15-35 ml/min - 50 mg/day (or 100 mg every other day), less than 15 ml/min - 50 mg every second day (or 100 mg 1 time every 4 day); for patients on hemodialysis - 25-50 mg/day immediately after dialysis. In elderly patients, the initial single dose is 25 mg (can be increased under the control of blood pressure and heart rate).
OVERDOSE Symptoms: bradycardia, AV block II-III degree, heart failure, respiratory failure, hypotension, bronchospasm, hypoglycemia. Treatment: gastric lavage and administration of adsorbents; symptomatic therapy: atropine, isoprenaline, orciprenaline, cardiac glycosides or glucagon, diuretics, vasopressors (dopamine, dobutamine or norepinephrine), selective beta-agonists, glucose solution (iv), installation of an artificial pacemaker. Dialysis is possible.
SPECIAL INSTRUCTIONS Restricted for use in: diabetes mellitus, hypoglycemia, chronic obstructive pulmonary diseases (emphysema, bronchial asthma), liver and/or kidney dysfunction, myasthenia gravis, depression, psoriasis, pheochromocytoma, metabolic acidosis, pregnancy, children (efficacy and safety not determined) and old age. Use during pregnancy and breastfeeding: Possible if the expected effect of therapy exceeds the potential risk to the fetus. Breastfeeding should be stopped during treatment. Treatment is carried out with regular medical supervision. Before starting therapy, heart failure should be compensated. During treatment, monitoring of heart rate, blood pressure, blood glucose levels is necessary (dosage adjustment of antidiabetic drugs is possible) and monitoring for the appearance of symptoms of heart failure. Use with caution while working for vehicle drivers and people whose profession involves increased concentration. It is recommended to avoid alcohol intake during therapy. For more detailed information, see the instructions for use.
STORAGE CONDITIONS List B. In a place protected from light, at room temperature no higher than 25 degrees. WITH
